Magnum Bold 300

History reference

Boldenone patented as a synthetic anabolic steroid in 1949, the company Ciba. During the 50s, 60s, Ciba experimented on various esters of the drug, then released boldenone undesilinate (a long-acting form). Magnum Bold 300 was known as parenabol, which most likely indicated the method of substance administration. In the 60s, 70s, parenabol had little clinical use, in particular in the treatment of dystrophy and increase in bone mass in osteoporosis. In the official market, the drug existed very little, it was no longer produced after the late 70s. Squibb supplied the drug to the veterinary market, naming it equipoise. It was used on different animals, but mostly on horseback. Subsequently, the adoption of the drug noted an increase in dry weight, a significant improvement in appetite and the condition of the animal as a whole. Squibb supplied equipoise to the market until 1985, until the firm’s sales cycle followed, and in 1995 Wyeth acquired the company’s assets. The veterinary part of the company is located in Fort Dodge, equipoise continues to produce and supply global markets, including the US. A large number of firms are engaged in the release of boldenone undensilata, since the terms of patents have long expired.

Magnum Bold 300 – side effects

The double bond between 1 and 2 carbon atoms is responsible for many properties of Equipoise. First of all, it inhibits the process of flavoring (turning into estrogen) drug. If you compare with testosterone, the conversion level of boldenone is two times lower. Athletes almost never notice the side effects of boldenone associated with estrogen (gynecomastia, edema, increased pressure), even if the dose of the drug reaches 1 g per week. This means that during the course of Equipoise there is no need to take anti-estrogens.

Low androgenic activity allows women to use equipoise. Virilization phenomena occur quite rarely compared with other drugs. Boldenone is one of the few injectables that can be used in female bodybuilding with the least risk of side effects.

The same double bond provides Ekvipoise resistance to the enzyme 5-alpha reductase. This enzyme converts a small amount of boldenone into dihydroboldenone, which is a powerful androgen (7 times more powerful than testosterone). Therefore, the drug practically does not cause such androgenic side effects as baldness, acne, prostate hypertrophy, etc., and also to a lesser extent suppresses testosterone production in the body.

Indications for medicinal use Magnum Bold 300 mg

In theory, the indications for the medicinal use of Magnum Bold 300 mg are somewhat dystrophy and an increase in bone mass in osteoporosis. Due to the fact that the drug for more than 40 years is used only in veterinary medicine, but at the moment there are no medical indications for the use of Boldenone Undecylenate in medicine.